Regeneron Pharmaceuticals a-t-elle un pricing power dans son secteur ?
14
Weak
Regeneron Pharmaceuticals shows weak pricing power. Margins are below industry norms and may be declining. The business appears to compete primarily on price, leaving it vulnerable to cost increases and competitive pressure on profitability.
Lisez le rapport complet sur Regeneron Pharmaceuticals et explorez les autres sections